Distinct disease features in chimpanzees infected with a precore HBV mutant associated with acute liver failure in humans.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
08 2020
Historique:
received: 06 04 2020
accepted: 08 07 2020
revised: 11 09 2020
pubmed: 1 9 2020
medline: 6 10 2020
entrez: 1 9 2020
Statut: epublish

Résumé

Transmission to chimpanzees of a precore hepatitis B virus (HBV) mutant implicated in acute liver failure (ALF) in humans did not cause ALF nor the classic form of acute hepatitis B (AHB) seen upon infection with the wild-type HBV strain, but rather a severe AHB with distinct disease features. Here, we investigated the viral and host immunity factors responsible for the unusual severity of AHB associated with the precore HBV mutant in chimpanzees. Archived serial serum and liver specimens from two chimpanzees inoculated with a precore HBV mutant implicated in ALF and two chimpanzees inoculated with wild-type HBV were studied. We used phage-display library and next-generation sequencing (NGS) technologies to characterize the liver antibody response. The results obtained in severe AHB were compared with those in classic AHB and HBV-associated ALF in humans. Severe AHB was characterized by: (i) the highest alanine aminotransferase (ALT) peaks ever seen in HBV transmission studies with a significantly shorter incubation period, compared to classic AHB; (ii) earlier HBsAg clearance and anti-HBs seroconversion with transient or undetectable hepatitis B e antigen (HBeAg); (iii) limited inflammatory reaction relative to hepatocellular damage at the ALT peak with B-cell infiltration, albeit less extensive than in ALF; (iv) detection of intrahepatic germline antibodies against hepatitis B core antigen (HBcAg) by phage-display libraries in the earliest disease phase, as seen in ALF; (v) lack of intrahepatic IgM anti-HBcAg Fab, as seen in classic AHB, but at variance with ALF; and (vi) higher proportion of antibodies in germline configuration detected by NGS in the intrahepatic antibody repertoire compared to classic AHB, but lower than in ALF. This study identifies distinct outcome-specific features associated with severe AHB caused by a precore HBV mutant in chimpanzees, which bear closer resemblance to HBV ALF than to classic AHB. Our data suggest that precore HBV mutants carry an inherently higher pathogenicity that, in addition to specific host factors, may play a critical role in determining the severity of acute HBV disease.

Identifiants

pubmed: 32866189
doi: 10.1371/journal.ppat.1008793
pii: PPATHOGENS-D-20-00690
pmc: PMC7485984
doi:

Substances chimiques

Hepatitis B Antibodies 0
Hepatitis B Core Antigens 0
Immunoglobulin M 0

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008793

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Infect Dis. 1975 Oct;132(4):451-8
pubmed: 1185011
Hepatology. 2003 Nov;38(5):1075-86
pubmed: 14578844
Immunol Rev. 2017 Jan;275(1):108-128
pubmed: 28133812
J Clin Invest. 1994 Feb;93(2):550-5
pubmed: 8113393
J Virol. 2009 Oct;83(19):9652-62
pubmed: 19625407
J Hepatol. 2019 Apr;70(4):615-625
pubmed: 30529504
J Virol. 2003 Jan;77(1):68-76
pubmed: 12477811
Lancet. 1986 Sep 6;2(8506):538-40
pubmed: 2875281
Am J Med Sci. 1975 Jul-Aug;270(1):17-31
pubmed: 171949
Gut. 1976 Jan;17(1):10-13
pubmed: 1269974
J Clin Invest. 1996 Nov 15;98(10):2268-76
pubmed: 8941643
Hepatology. 1991 Aug;14(2):219-22
pubmed: 1860679
J Clin Oncol. 2009 Feb 1;27(4):605-11
pubmed: 19075267
Nature. 1979 Oct 25;281(5733):646-50
pubmed: 399327
Transfusion. 2014 Nov;54(11):2833-41
pubmed: 24797372
Liver Int. 2017 Jul;37(7):995-1001
pubmed: 27992681
Immunogenetics. 2013 Sep;65(9):691-702
pubmed: 23793106
N Engl J Med. 2001 Jan 4;344(1):68-9
pubmed: 11187122
J Virol. 1997 Mar;71(3):2192-201
pubmed: 9032353
J Clin Invest. 1992 Dec;90(6):2481-90
pubmed: 1469099
Vox Sang. 2001 Jan;80(1):63-71
pubmed: 11339072
N Engl J Med. 1991 Jun 13;324(24):1705-9
pubmed: 2034247
Virology. 1993 May;194(1):263-76
pubmed: 8480422
Annu Rev Immunol. 1995;13:29-60
pubmed: 7612225
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8766-71
pubmed: 20421498
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6669-74
pubmed: 15100412
Aliment Pharmacol Ther. 2018 Jan;47(1):43-54
pubmed: 29035003
Nature. 2019 Feb;566(7744):398-402
pubmed: 30760926
J Virol. 2007 Sep;81(17):8989-95
pubmed: 17581986
Biology (Basel). 2012 Dec 14;1(3):895-905
pubmed: 24832523
Lancet. 2019 Sep 7;394(10201):869-881
pubmed: 31498101
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
J Hepatol. 2016 Apr;64(1 Suppl):S71-S83
pubmed: 27084039
N Engl J Med. 1993 Dec 16;329(25):1862-72
pubmed: 8305063
Intervirology. 1999;42(2-3):69-80
pubmed: 10516463
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W34-40
pubmed: 23671333
Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11369-E11378
pubmed: 30420516
J Virol. 1992 Sep;66(9):5682-4
pubmed: 1501300
Nature. 2019 Feb;566(7744):393-397
pubmed: 30664748
Gastroenterology. 2006 Jul;131(1):59-68
pubmed: 16831590
Gastroenterology. 1976 Oct;71(4):635-40
pubmed: 60267
Gut. 1983 Jul;24(7):615-7
pubmed: 6862284

Auteurs

Zhaochun Chen (Z)

Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Ronald E Engle (RE)

Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Chen-Hsiang Shen (CH)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Huaying Zhao (H)

Laboratory of Cellular Imaging and Macromolecular Biophysics, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, United States of America.

Peter W Schuck (PW)

Laboratory of Cellular Imaging and Macromolecular Biophysics, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, United States of America.

Emily J Danoff (EJ)

Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Hanh Nguyen (H)

Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Norihisa Nishimura (N)

Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Kevin W Bock (KW)

Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Ian N Moore (IN)

Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Peter D Kwong (PD)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Robert H Purcell (RH)

Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Sugantha Govindarajan (S)

Department of Pathology, University of Southern California, Los Angeles, California, United States of America.

Patrizia Farci (P)

Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH